DK1276853T3 - Pneumovirus NS-proteiner, der antagoniserer interferon (IFN)-responset - Google Patents

Pneumovirus NS-proteiner, der antagoniserer interferon (IFN)-responset

Info

Publication number
DK1276853T3
DK1276853T3 DK01929607T DK01929607T DK1276853T3 DK 1276853 T3 DK1276853 T3 DK 1276853T3 DK 01929607 T DK01929607 T DK 01929607T DK 01929607 T DK01929607 T DK 01929607T DK 1276853 T3 DK1276853 T3 DK 1276853T3
Authority
DK
Denmark
Prior art keywords
ifn
interferon
pneumovirus
protein
immune response
Prior art date
Application number
DK01929607T
Other languages
Danish (da)
English (en)
Inventor
Karl-Klaus Prof Dr Conzelmann
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of DK1276853T3 publication Critical patent/DK1276853T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK01929607T 2000-04-26 2001-04-26 Pneumovirus NS-proteiner, der antagoniserer interferon (IFN)-responset DK1276853T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10020505A DE10020505A1 (de) 2000-04-26 2000-04-26 RSV NS Proteine antagonisieren die Interferon (IFN) Antwort

Publications (1)

Publication Number Publication Date
DK1276853T3 true DK1276853T3 (da) 2006-10-30

Family

ID=7640025

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01929607T DK1276853T3 (da) 2000-04-26 2001-04-26 Pneumovirus NS-proteiner, der antagoniserer interferon (IFN)-responset

Country Status (17)

Country Link
US (2) US20030133911A1 (ko)
EP (1) EP1276853B1 (ko)
JP (1) JP2004504274A (ko)
KR (1) KR100584831B1 (ko)
CN (1) CN100473721C (ko)
AT (1) ATE336570T1 (ko)
AU (2) AU2001256327B2 (ko)
BR (1) BR0110384A (ko)
CA (1) CA2407053A1 (ko)
CY (1) CY1105704T1 (ko)
DE (2) DE10020505A1 (ko)
DK (1) DK1276853T3 (ko)
ES (1) ES2271005T3 (ko)
IL (1) IL152326A0 (ko)
MX (1) MXPA02010465A (ko)
PT (1) PT1276853E (ko)
WO (1) WO2001081554A1 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU771110B2 (en) 1998-06-12 2004-03-11 Mount Sinai School Of Medicine Of The City University Of New York, The Novel methods and interferon deficient substrates for the propagation of viruses
AU2001257001A1 (en) 2000-04-10 2001-10-23 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
CA2610632C (en) 2004-06-01 2022-10-04 Mount Sinai School Of Medicine Of New York University Genetically engineered swine influenza virus and uses thereof
EP1855713B1 (en) 2005-02-15 2016-04-27 Mount Sinai School of Medicine Genetically engineered equine influenza virus and uses thereof
EP2190979A4 (en) * 2007-08-31 2011-08-24 Aeras Global Tb Vaccine Foundation IMPROVEMENT OF TRANSGENEXPRESSION OF VIRUS-BASED VACCINE VACCINORS BY EXPRESSION OF TYPE I INTERFERON ANSWER TYPE-I SUPPRESSORS
CN102021149B (zh) * 2010-07-27 2013-04-24 张卫东 基因ns1缺陷型呼吸道合胞病毒及其治疗肺癌的应用
EP3261664A1 (en) 2015-02-26 2018-01-03 Boehringer Ingelheim Vetmedica GmbH Bivalent swine influenza virus vaccine
WO2017030997A1 (en) * 2015-08-14 2017-02-23 Research Institute At Nationwide Children's Hospital Respiratory syncytial virus having altered ns1 protein function and related materials and methods
CN111214495B (zh) * 2020-03-02 2021-12-31 广西医科大学第一附属医院 注射用母牛分枝杆菌在制备用于防治呼吸系rsv感染的药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6923971B2 (en) * 1995-09-27 2005-08-02 The United States Of America As Represented By The Department Of Health & Human Services Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
AU7719596A (en) * 1995-11-07 1997-05-29 Baylor College Of Medicine Adenovirus-mediated production of bioactive proteins by mammalian cells and animals
WO1998002530A1 (en) * 1996-07-15 1998-01-22 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
US6699476B1 (en) * 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
US6844188B1 (en) * 1998-04-08 2005-01-18 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
AU771110B2 (en) * 1998-06-12 2004-03-11 Mount Sinai School Of Medicine Of The City University Of New York, The Novel methods and interferon deficient substrates for the propagation of viruses
AU2002368225A1 (en) * 2001-10-10 2004-05-04 Mount Sinai School Of Medicine Of The City University Of New York Viral interferon antagonists and uses therefor

Also Published As

Publication number Publication date
PT1276853E (pt) 2006-11-30
US7700092B2 (en) 2010-04-20
US20080160039A1 (en) 2008-07-03
JP2004504274A (ja) 2004-02-12
CN100473721C (zh) 2009-04-01
EP1276853B1 (de) 2006-08-16
DE50110752D1 (de) 2006-09-28
BR0110384A (pt) 2003-02-11
DE10020505A1 (de) 2001-10-31
ES2271005T3 (es) 2007-04-16
KR20020097232A (ko) 2002-12-31
AU2001256327B2 (en) 2005-06-09
CN1426462A (zh) 2003-06-25
ATE336570T1 (de) 2006-09-15
CA2407053A1 (en) 2001-11-01
KR100584831B1 (ko) 2006-05-29
EP1276853A1 (de) 2003-01-22
IL152326A0 (en) 2003-05-29
WO2001081554A1 (de) 2001-11-01
CY1105704T1 (el) 2010-12-22
AU5632701A (en) 2001-11-07
US20030133911A1 (en) 2003-07-17
MXPA02010465A (es) 2003-06-26

Similar Documents

Publication Publication Date Title
NO20006328D0 (no) Attenuerte negative trådvirus med endret interferonantagonistaktivitet for anvendelse som vaksiner og medikamenter
WO2006083286A3 (en) Genetically engineered swine influenza virus and uses thereof
EA200602257A1 (ru) Стабилизированные жидкие препаративные формы интерферона
WO2006088481A3 (en) Genetically engineered equine influenza virus and uses thereof
CY1105704T1 (el) Πρωτεϊνες του πνευμονοϊου ns ανταγωνιζονται την ανταποκριση της ιντερφερονης(ifn)
WO2018109220A3 (en) Novel recombinant prefusion rsv f proteins and uses thereof
WO2003072720A3 (en) Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
WO2010007622A3 (en) Long-acting interferons and derivatives thereof and methods thereof
WO2005027825A3 (en) Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
HUP0401818A2 (hu) Eljárás hepatitis vírusfertőzés kezelésére multifázisos interferon felszabadulású profillal
EA200501699A1 (ru) Стабилизированные жидкие композиции интерферона, не содержащие человеческий сывороточный альбумин
MX2022014167A (es) Replicón de arn que codifica una proteína de espícula del coronavirus estabilizada.
DK1949913T3 (da) Immunstimulatorisk kombination til profylakserne og behandlingen af hepatitis C
TW200502246A (en) Vaccine
Skorvanova et al. Protective efficacy of IFN-ω AND IFN-λs against influenza viruses in induced A549 cells
WO2022266511A8 (en) Temperature-controllable, self-replicating rna vaccines for viral diseases
WO2005056051A3 (en) Hepatitis b vaccines and compositions
HRP20140819T1 (hr) MUTIRANI TAT OYI PROTEIN ZA PREVENCIJU ILI LIJEÄŚENJE AIDS-a
WO2004092207A3 (en) Respiratory syncytial virus (rsv) peptides
ITRM20010336A0 (it) Anticorpo umano ricombinante diretto contro la proteina non strutturale ns3 del virus dell'epatite c (hcv), acido nucleico codificante e usi
WO2003102014A3 (en) Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
WO2004009802A3 (en) gM-NEGATIVE EHV-MUTANTS WITHOUT HETEROLOGOUS ELEMENTS
WO2003007986A8 (es) Formulacion vacunal potenciada por la combinacion de un adn con un antigeno
WO2004046168A3 (en) Recombinant hiv-1 subclass d envelope glycoproteins
BRPI0514274A (pt) vìrus de varìola aviária recombinante e composição farmacêutica para induzir uma resposta imune celular especìfica contra o vhc